AU2001253119B2 - A gene differentially expressed in breast and bladder cancer and encoded polypeptides - Google Patents

A gene differentially expressed in breast and bladder cancer and encoded polypeptides Download PDF

Info

Publication number
AU2001253119B2
AU2001253119B2 AU2001253119A AU2001253119A AU2001253119B2 AU 2001253119 B2 AU2001253119 B2 AU 2001253119B2 AU 2001253119 A AU2001253119 A AU 2001253119A AU 2001253119 A AU2001253119 A AU 2001253119A AU 2001253119 B2 AU2001253119 B2 AU 2001253119B2
Authority
AU
Australia
Prior art keywords
amino acids
seq
peptide
epitope
peptide epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001253119A
Other languages
English (en)
Other versions
AU2001253119A1 (en
AU2001253119A2 (en
Inventor
Melinda A. Borrello
Elizabeth E. Evans
Maurice Zauderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of AU2001253119A1 publication Critical patent/AU2001253119A1/en
Publication of AU2001253119A2 publication Critical patent/AU2001253119A2/en
Application granted granted Critical
Publication of AU2001253119B2 publication Critical patent/AU2001253119B2/en
Priority to AU2006202984A priority Critical patent/AU2006202984B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001253119A 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides Ceased AU2001253119B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006202984A AU2006202984B2 (en) 2000-04-04 2006-07-12 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19446300P 2000-04-04 2000-04-04
US60/194,463 2000-04-04
PCT/US2001/010855 WO2001074859A2 (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006202984A Division AU2006202984B2 (en) 2000-04-04 2006-07-12 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Publications (3)

Publication Number Publication Date
AU2001253119A1 AU2001253119A1 (en) 2002-01-03
AU2001253119A2 AU2001253119A2 (en) 2003-03-27
AU2001253119B2 true AU2001253119B2 (en) 2006-04-13

Family

ID=22717696

Family Applications (2)

Application Number Title Priority Date Filing Date
AU5311901A Pending AU5311901A (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2001253119A Ceased AU2001253119B2 (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU5311901A Pending AU5311901A (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Country Status (10)

Country Link
US (3) US7268207B2 (enExample)
EP (1) EP1272636B8 (enExample)
JP (1) JP2004502408A (enExample)
CN (2) CN101643732A (enExample)
AT (1) ATE404669T1 (enExample)
AU (2) AU5311901A (enExample)
CA (1) CA2413211A1 (enExample)
DE (1) DE60135315D1 (enExample)
NZ (1) NZ522282A (enExample)
WO (1) WO2001074859A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074859A2 (en) * 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
EP1359937A4 (en) * 2001-02-14 2004-07-28 Genzyme Corp MODIFIED PEPTIDE LIGANDS
US7705120B2 (en) 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP4643255B2 (ja) 2002-06-10 2011-03-02 バクシネックス インコーポレーティッド 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
WO2004087058A2 (en) * 2003-03-28 2004-10-14 Vaccinex, Inc. Targeted mhc class i alpha3 vaccine delivery systems
WO2005099361A2 (en) * 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
WO2005055936A2 (en) * 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
JP2007530075A (ja) * 2004-04-23 2007-11-01 エグザジェン ダイアグノスティクス インコーポレイテッド 乳がんの予後診断のための組成物および方法
CA2656918A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
CA2678618C (en) * 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
AU2010203451B2 (en) 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
WO2010111792A1 (en) * 2009-04-01 2010-10-07 The University Of British Columbia Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
EP2480563B1 (en) * 2009-09-24 2017-02-22 The Regents of The University of California Bladder cancer specific ligand peptides
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
AU2016369519B2 (en) * 2015-12-16 2023-04-20 Seattle Project Corp. Neoantigen identification, manufacture, and use
KR20200066305A (ko) * 2017-09-05 2020-06-09 그릿스톤 온콜로지, 인코포레이티드 T-세포 치료를 위한 신생항원 식별
CA3078744A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
CN112243463B (zh) 2018-04-09 2024-12-13 小利兰·斯坦福大学托管委员会 原位基因测序方法
KR102318018B1 (ko) 2019-07-05 2021-10-28 한국생산기술연구원 마이크로 제품 제작용 맨드렐 제작 방법, 마이크로 제품 제작용 몰드 제작 방법 및 마이크로 제품 제작용 몰드
CN120700116A (zh) * 2019-10-18 2025-09-26 小利兰·斯坦福大学董事会 临床和工业规模的完整组织测序
CN115407064B (zh) * 2021-05-26 2025-09-23 复旦大学附属肿瘤医院 肿瘤干细胞血管拟态标志物tem8在制备诊断试剂和试剂盒中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3869400A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human cancer associated gene sequences and polypeptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0581600A (ja) * 1991-04-18 1993-04-02 Fujitsu Ltd 双曲線航法システムにおけるシステム監視処理方式
EP0656788B1 (en) 1992-08-07 2006-10-18 Pharmexa Inc. Hla binding peptides and their uses
DE69435292D1 (de) 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
US5856131A (en) * 1997-02-24 1999-01-05 Incyte Pharmaceuticals, Inc. Human selenoprotein
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
AU2010699A (en) * 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
AU2342299A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating breast cancer
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
EP1248800A2 (en) * 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
WO2001074859A2 (en) 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20030166277A1 (en) 2000-04-12 2003-09-04 University Of Rochester Targeted vaccine delivery systems
WO2002102855A2 (en) 2000-11-17 2002-12-27 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20050196755A1 (en) 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
JP4643255B2 (ja) 2002-06-10 2011-03-02 バクシネックス インコーポレーティッド 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド
WO2005099361A2 (en) 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
WO2005055936A2 (en) 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3869400A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human cancer associated gene sequences and polypeptides

Also Published As

Publication number Publication date
EP1272636A2 (en) 2003-01-08
JP2004502408A (ja) 2004-01-29
AU5311901A (en) 2001-10-15
ATE404669T1 (de) 2008-08-15
WO2001074859A3 (en) 2002-03-28
EP1272636B8 (en) 2008-10-08
EP1272636B1 (en) 2008-08-13
US20020155447A1 (en) 2002-10-24
US7910551B2 (en) 2011-03-22
DE60135315D1 (de) 2008-09-25
US7268207B2 (en) 2007-09-11
CN1610743A (zh) 2005-04-27
US20070081942A1 (en) 2007-04-12
US20090312263A1 (en) 2009-12-17
CA2413211A1 (en) 2001-10-11
NZ522282A (en) 2005-03-24
WO2001074859A2 (en) 2001-10-11
CN101643732A (zh) 2010-02-10

Similar Documents

Publication Publication Date Title
AU2001253119B2 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7750125B2 (en) Antibodies that bind to the C35 polypeptide
AU2001253119A2 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
CA2345817C (en) Novel methods for therapeutic vaccination
EP0752876B1 (en) Monoclonal anbibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides
JPH04501719A (ja) ポリペプチド
JP2002541833A (ja) ４９個のヒト分泌タンパク質
AU781925B2 (en) T-cell receptor gamma alternate reading frame protein, (TARP) and uses thereof
AU2006202984B2 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1788085A1 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
ZA200102603B (en) Novel methods for therapeutic vaccination.
NZ548918A (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides
CN101173285A (zh) 在乳腺癌和膀胱癌中差异表达的基因及编码多肽
JP2002538807A (ja) ５０個のヒト分泌タンパク質

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 JAN 2003

MK14 Patent ceased section 143(a) (annual fees not paid) or expired